In vitro cardiac new approach methodologies predict clinical cardiovascular repolarization risk comparable to non-clinical animal studies
Lab-grown heart cells predict drug toxicity as reliably as animal studies, opening a path to reduce animal testing in pharmaceutical development.
An FDA analysis of 20+ IND applications found that hiPSC-derived cardiomyocyte assays predict clinical QT prolongation as well as traditional animal studies (concordance 0.71–0.82 vs 0.78), providing regulatory evidence to reduce animal testing in cardiac safety assessment. This is a significant step toward integrating non-animal new approach methodologies (NAMs) into drug approval workflows.
What the study was
- Study design
- Retrospective FDA regulatory analysis of IND applications (pilot study, n>20 INDs)
- Population
- Investigational New Drug applications submitted to FDA 2020–2023 with hiPSC-CM and/or animal QT data (23 drugs: 5 QT+ and 18 QT-)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Br J Pharmacol
Why it surfaced
FDA regulatory pilot provides direct policy pathway for hiPSC-CM adoption in IND filings. Small pilot (n>20 INDs, only 5 QT+ drugs) limits statistical power but regulatory provenance is uniquely actionable.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.